Effect of Triglyceride-Glucose Indices and Circulating PCSK9-Associated Cardiovascular Risk in STEMI Patients with Primary Percutaneous Coronary Artery Disease: A Prospective Cohort Study

References

• Zhang D-W, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epider- mal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282:18602–18612. doi:10.1074/jbc.M702027200
   PubMed Web of Science ®Google Scholar
• Li C, Lin L, Zhang W, et al. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. J Am Heart Assoc. 2015;4:e001937. doi:10.1161/JAHA.115.001937
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi:10.1056/NEJMoa1615664
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107. doi:10.1056/NEJMoa1801174
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the Fourier randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941–950. doi:10.1016/S2213-8587(17)30313-3
   PubMed Web of Science ®Google Scholar
• Tang Y, Li SL, Hu JH, Sun KJ, Liu LL, Xu DY. Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes. Cardiovasc Diabetol. 2020;19(1):33. doi:10.1186/s12933-020-01009-4
   PubMed Web of Science ®Google Scholar
• Ferri N, Marchianò S, Tibolla G, et al. PCSK9 knock-out mice are protected from neoin- timal formation in response to perivascular carotid collar placement. Atherosclerosis. 2016;253:214–224. doi:10.1016/j.atherosclerosis.2016.07.910
   PubMed Web of Science ®Google Scholar
• Camera M, Rossetti L, Barbieri SS, et al. PCSK9 as a positive modulator of platelet activation. J Am Coll Cardiol. 2018;71(8):952–954. doi:10.1016/j.jacc.2017.11.069
   PubMed Web of Science ®Google Scholar
• Gencer B, Mach F, Murphy SA, et al. Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the Fourier trial. JAMA Cardiol. 2020;5(8):952–957. doi:10.1001/jamacardio.2020.0882
   PubMed Web of Science ®Google Scholar
• Da Dalt L, Ruscica M, Bonacina F, et al. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. Eur Heart J. 2019;40(4):357–368. doi:10.1093/eurheartj/ehy357
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397. doi:10.1056/NEJMoa1410489
   PubMed Web of Science ®Google Scholar
• Guerrero-Romero F, Simental-Mendia LE, Gonzalez-Ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Com- parison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347–3351. doi:10.1210/jc.2010-0288
   PubMed Web of Science ®Google Scholar
• Mazidi M, Kengne AP, Katsiki N, Mikhailidis DP, Banach M. Lipid accumula- tion product and triglycerides/glucose index are useful predictors of insulin resistance. J Diabetes Complicat. 2018;32(3):266–270. doi:10.1016/j.jdiacomp.2017.10.007
   PubMed Web of Science ®Google Scholar
• Du T, Yuan G, Zhang M, Zhou X, Sun X, Yu X. Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glu- cose index as risk markers of insulin resistance. Cardiovasc Diabetol. 2014;13:146. doi:10.1186/s12933-014-0146-3
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–177. doi:10.1093/eurheartj/ehx393
   PubMed Web of Science ®Google Scholar
• Aronow WS. Hypertension guidelines. Hypertension. 2011;58(3):347–348. doi:10.1161/HYPERTENSIONAHA.111.177147
   PubMed Web of Science ®Google Scholar
• Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39(6):861–877. doi:10.2337/dc16-0236
   PubMed Web of Science ®Google Scholar
• Shrank WH, Barlow JF, Brennan TA. New therapies in the treatment of high cholesterol: an argument to return to goal-based lipid guidelines. JAMA J Am Med Assoc. 2015;314(14):1443–1444. doi:10.1001/jama.2015.10017
   PubMed Web of Science ®Google Scholar
• Lin L, Zhao J, Hu J, et al. Current smoking has a detrimental effect on survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) patients treated with pemetrexed continuation maintenance. J Cancer. 2018;9(12):2140–2146. doi:10.7150/jca.24872
   PubMed Web of Science ®Google Scholar
• Stevens PE, Levin A; Kidney disease: improving global outcomes chronic kidney disease guideline development work group, M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–830. doi:10.7326/0003-4819-158-11-201306040-00007
   PubMed Web of Science ®Google Scholar
• Caselli C, Del Turco S, Ragusa R, et al. Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. Cardiovasc Diabetol. 2019;18(1):144. doi:10.1186/s12933-019-0949-3
   PubMed Web of Science ®Google Scholar
• Yang SH, Xu RX, Cui CJ, et al. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. Cardiovasc Diabetol. 2018;17(1):48. doi:10.1186/s12933-018-0689-9
   PubMed Web of Science ®Google Scholar
• Peng J, Liu MM, Jin JL, et al. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. Cardiovasc Diabetol. 2020;19(1):167. doi:10.1186/s12933-020-01142-0
   PubMed Web of Science ®Google Scholar
• Wang Y, Ye J, Li J, et al. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9). Cardiovasc Diabetol. 2016;15:19. doi:10.1186/s12933-015-0325-x
   PubMed Web of Science ®Google Scholar
• Levenson AE, Wadwa RP, Shah AS, et al. PCSK9 is increased in youth with type 1 diabetes. Diabetes Care. 2017;40(7):e85–7. doi:10.2337/dc16-2563
   PubMed Web of Science ®Google Scholar
• Levenson AE, Shah AS, Khoury PR, Kimball TR, Urbina EM, de Ferranti SD. Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women. Pediatr Diabetes. 2017;18(8):755–760. doi:10.1111/pedi.12490
   PubMed Web of Science ®Google Scholar
• Bojanin D, Vekic J, Milenkovic T, et al. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: effects of glycemic control. Atherosclerosis. 2019;280:14–20. doi:10.1016/j.atherosclerosis.2018.11.020
   PubMed Web of Science ®Google Scholar
• Ramin-Mangata S, Wargny M, Pichelin M, et al. Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes. Atherosclerosis. 2019;293:49–56. doi:10.1016/j.atherosclerosis.2019.11.027
   PubMed Web of Science ®Google Scholar
• Reyes-Sofer G, Pavlyha M, Ngai C, et al. Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation. 2017;135(4):352–362. doi:10.1161/CIRCULATIONAHA.116.025253
   PubMed Web of Science ®Google Scholar
• Shi J, Zhang W, Niu Y, et al. Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study. Cardiovasc Diabetol. 2020;19(1):209. doi:10.1186/s12933-020-01185-3
   PubMed Web of Science ®Google Scholar
• Schmidt AF, Swerdlow DI, Holmes MV, et al. PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2017;5:97–105. doi:10.1016/S2213-8587(16)30396-5
   PubMed Web of Science ®Google Scholar
• Lotta LA, Sharp SJ, Burgess S, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA. 2016;316:1383–1391. doi:10.1001/jama.2016.14568
   PubMed Web of Science ®Google Scholar
• Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes. 2007;56:2328–2338. doi:10.2337/db07-0056
   PubMed Web of Science ®Google Scholar
• Paul R, Choudhury A, Choudhury S, Mazumder MK, Borah A. Cholesterol in pancreatic beta-cell death and dysfunction: underlying mechanisms and pathological implications. Pancreas. 2016;45:317–324. doi:10.1097/MPA.0000000000000486
   PubMed Web of Science ®Google Scholar
• Brunham LR, Kruit JK, Pape TD, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007;13:340–347. doi:10.1038/nm1546
   PubMed Web of Science ®Google Scholar
• Brunham LR, Kruit JK, Verchere CB, Hayden MR. Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest. 2008;118:403–408. doi:10.1172/JCI33296
   PubMed Web of Science ®Google Scholar
• Cochran BJ, Hou L, Manavalan AP, et al. Impact of perturbed pancreatic beta-cell cholesterol homeostasis on adipose tissue and skeletal muscle metabolism. Diabetes. 2016;65:3610–3620. doi:10.2337/db16-0668
   PubMed Web of Science ®Google Scholar
• Hopkins PN, Krempf M, Bruckert E, et al. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations. J Clin Lipidol. 2019;13(6):970–978. doi:10.1016/j.jacl.2019.10.007
   PubMed Web of Science ®Google Scholar